AVIR insider transaction filings
Atea Pharmaceuticals, Inc. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-23. Screen AVIR transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for AVIR between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — Atea Pharmaceuticals, Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-23 | 4 | Lucidi Bruno — Director | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Berman Howard — Director | Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Adams Jerome M. — Director | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Murphy Polly A. — Director | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | Polsky Bruce — Director | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | DUNCAN BARBARA GAYLE — Director | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | KIRSCH ARTHUR S — Director | Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-06-23 | 4 | BERGER FRANKLIN M — Director | Option exercise (M): 29,600 @ $0 · Option exercise (M): 29,600 (derivative) @ $0 · Grant/award (A): 26,700 (derivative) @ $0 · Grant/award (A): 37,700 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4/A | Murphy Polly A. — Director | Purchase (P): 6,100 @ $4.17 | EDGAR |
| 2026-05-20 | 4 | Murphy Polly A. — Director | Purchase (P): 6,100 @ $4.17 | EDGAR |
| 2026-03-13 | 4 | Corcoran Andrea — See Remarks | Option exercise (M): 60,000 @ $1.24 · Option exercise (M): 60,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Horga Maria Arantxa — Chief Medical Officer | Option exercise (M): 51,283 · Tax withholding (F): 16,073 @ $4.24 · Option exercise (M): 41,533 (derivative) @ $0 · Option exercise (M): 9,750 (derivative) @ $0 · Grant/award (A): 173,500 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Vavricka John — Chief Commercial Officer | Option exercise (M): 42,083 · Tax withholding (F): 11,570 @ $4.24 · Option exercise (M): 33,333 (derivative) @ $0 · Option exercise (M): 8,750 (derivative) @ $0 · Grant/award (A): 119,520 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Hammond Janet MJ — Chief Development Officer | Option exercise (M): 58,050 · Tax withholding (F): 14,136 @ $4.24 · Option exercise (M): 46,800 (derivative) @ $0 · Option exercise (M): 11,250 (derivative) @ $0 · Grant/award (A): 177,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Foster Wayne — EVP, Chief Accounting Officer | Option exercise (M): 41,333 · Tax withholding (F): 12,132 @ $4.24 · Option exercise (M): 33,333 (derivative) @ $0 · Option exercise (M): 8,000 (derivative) @ $0 · Grant/award (A): 108,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Corcoran Andrea — See Remarks | Option exercise (M): 54,866 · Tax withholding (F): 16,104 @ $4.24 · Option exercise (M): 44,366 (derivative) @ $0 · Option exercise (M): 10,500 (derivative) @ $0 · Grant/award (A): 180,000 (derivative) @ $0 | EDGAR |
| 2026-02-03 | 4 | Sommadossi Jean-Pierre — President, CEO, and Chairman, Director | Option exercise (M): 272,983 · Tax withholding (F): 106,093 @ $4.24 · Option exercise (M): 300,000 @ $1.24 · Option exercise (M): 173,466 (derivative) @ $0 · Option exercise (M): 99,517 (derivative) @ $0 · Option exercise (M): 300,000 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Adams Jerome M. — Director | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Murphy Polly A. — Director | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Lucidi Bruno — Director | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Berman Howard — Director | Grant/award (A): 164,800 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Polsky Bruce — Director | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Duncan Barbara Gayle — Director | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | BERGER FRANKLIN M — Director | Option exercise (M): 29,600 @ $0 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 · Option exercise (M): 29,600 (derivative) @ $0 | EDGAR |
| 2025-02-24 | 4 | Kirsch Arthur S — Director | Grant/award (A): 164,800 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Hammond Janet MJ — Chief Development Officer | Option exercise (M): 46,800 · Grant/award (A): 11,250 · Tax withholding (F): 14,134 @ $3.06 · Option exercise (M): 46,800 (derivative) @ $0 · Grant/award (A): 11,250 (derivative) @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Vavricka John — Chief Commercial Officer | Option exercise (M): 33,333 · Grant/award (A): 8,750 · Tax withholding (F): 11,517 @ $3.06 · Option exercise (M): 33,333 (derivative) @ $0 · Grant/award (A): 8,750 (derivative) @ $0 · Grant/award (A): 132,800 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Horga Maria Arantxa — Chief Medical Officer | Option exercise (M): 41,533 · Grant/award (A): 9,750 · Tax withholding (F): 16,071 @ $3.06 · Option exercise (M): 41,533 (derivative) @ $0 · Grant/award (A): 9,750 (derivative) @ $0 · Grant/award (A): 192,800 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Foster Wayne — EVP, Chief Accounting Officer | Option exercise (M): 33,333 · Grant/award (A): 8,000 · Tax withholding (F): 12,062 @ $3.06 · Option exercise (M): 33,333 (derivative) @ $0 · Grant/award (A): 8,000 (derivative) @ $0 · Grant/award (A): 120,100 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Corcoran Andrea — See Remarks | Option exercise (M): 44,367 · Grant/award (A): 10,500 · Tax withholding (F): 16,102 @ $3.06 · Option exercise (M): 44,367 (derivative) @ $0 · Grant/award (A): 10,500 (derivative) @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2025-02-04 | 4 | Sommadossi Jean-Pierre — President, CEO, and Chairman, Director | Option exercise (M): 173,467 · Grant/award (A): 99,517 · Tax withholding (F): 88,601 @ $3.06 · Option exercise (M): 173,467 (derivative) @ $0 · Grant/award (A): 99,518 (derivative) @ $0 · Grant/award (A): 440,000 (derivative) @ $0 | EDGAR |
| 2025-01-17 | 4 | BERGER FRANKLIN M — Director | Purchase (P): 15,000 @ $3.19 · Purchase (P): 10,000 @ $3.36 | EDGAR |
| 2025-01-17 | 4/A | BERGER FRANKLIN M — Director | Purchase (P): 15,000 @ $3.19 · Purchase (P): 10,000 @ $3.36 | EDGAR |
| 2024-12-12 | 4 | BERGER FRANKLIN M — Director | Sale (S): 359,606 @ $2.85 | EDGAR |
| 2024-09-19 | 4 | Sommadossi Jean-Pierre — President, CEO, and Chairman, Director | Sale (S): 33,941 @ $4.05 · Sale (S): 22,187 @ $4.03 · Sale (S): 1,841 @ $4.00 | EDGAR |
| 2024-06-21 | 4 | Adams Jerome M. — Director | Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Lucidi Bruno — Director | Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Murphy Polly A. — Director | Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Polsky Bruce — Director | Sale (S): 17,544 @ $3.49 · Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | Duncan Barbara Gayle — Director | Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-21 | 4 | BERGER FRANKLIN M — Director | Grant/award (A): 29,600 (derivative) @ $0 · Grant/award (A): 41,200 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Murphy Polly A. — Director | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Lucidi Bruno — Director | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Adams Jerome M. — Director | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Polsky Bruce — Director | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Duncan Barbara Gayle — Director | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | BERGER FRANKLIN M — Director | Option exercise (M): 33,150 @ $0 · Option exercise (M): 33,150 (derivative) @ $0 | EDGAR |
| 2024-06-07 | 4 | Sommadossi Jean-Pierre — President, CEO, and Chairman, Director | Sale (S): 1,006 @ $4 | EDGAR |
| 2024-02-02 | 4 | Corcoran Andrea — See Remarks | Option exercise (M): 44,367 · Sale (S): 15,843 @ $3.84 · Option exercise (M): 44,367 (derivative) @ $0 · Grant/award (A): 200,000 (derivative) @ $0 | EDGAR |
| 2024-02-02 | 4 | Sommadossi Jean-Pierre — President, CEO, and Chairman, Director | Option exercise (M): 173,467 · Sale (S): 56,910 @ $3.85 · Option exercise (M): 173,467 (derivative) @ $0 · Grant/award (A): 448,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Atea Pharmaceuticals, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-11-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-06-20 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-05-12 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-04-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=AVIR returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →